See more : Equinox Gold Corp. (EQX.TO) Income Statement Analysis – Financial Results
Complete financial analysis of Mangoceuticals, Inc. (MGRX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Mangoceuticals, Inc., a leading company in the Medical – Healthcare Information Services industry within the Healthcare sector.
You may be interested
- Curzon Energy Plc (CZN.L) Income Statement Analysis – Financial Results
- Zenrin Co., Ltd. (9474.T) Income Statement Analysis – Financial Results
- Prime Meridian Resources Corp. (PMDRF) Income Statement Analysis – Financial Results
- Nordea Invest – Korte obligationer Lagerbeskattet (NDIKOLKL1.CO) Income Statement Analysis – Financial Results
- Gujarat Industries Power Company Limited (GIPCL.NS) Income Statement Analysis – Financial Results
Mangoceuticals, Inc. (MGRX)
Industry: Medical - Healthcare Information Services
Sector: Healthcare
Website: https://www.mangorx.com
About Mangoceuticals, Inc.
Mangoceuticals, Inc. focuses on develops, markets, and sells various men's wellness products and services through a telemedicine platform. It offers erectile dysfunction products under the Mango brand name. The company sells its products through online website mangorx.com. Mangoceuticals, Inc. was incorporated in 2021 and is headquartered in Dallas, Texas. Mangoceuticals, Inc. operates as a subsidiary of Cohen Enterprises, Inc.
| Metric | 2023 | 2022 | 2021 |
|---|---|---|---|
| Revenue | 731.49K | 8.94K | 0.00 |
| Cost of Revenue | 299.99K | 4.09K | 0.00 |
| Gross Profit | 431.50K | 4.85K | 0.00 |
| Gross Profit Ratio | 58.99% | 54.26% | 0.00% |
| Research & Development | 0.00 | 0.00 | 0.00 |
| General & Administrative | 6.45M | 2.00M | 70.08K |
| Selling & Marketing | 2.10M | 352.86K | -52.56K |
| SG&A | 8.55M | 2.00M | 17.52K |
| Other Expenses | 1.10M | 0.00 | 0.00 |
| Operating Expenses | 9.65M | 2.00M | 17.52K |
| Cost & Expenses | 9.95M | 2.00M | 17.52K |
| Interest Income | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 6.47K | 181.00 |
| Depreciation & Amortization | 24.89K | 3.86K | 70.08K |
| EBITDA | -9.19M | -1.99M | 52.56K |
| EBITDA Ratio | -1,256.00% | -22,236.48% | 0.00% |
| Operating Income | -9.22M | -1.99M | -17.52K |
| Operating Income Ratio | -1,260.28% | -22,279.70% | 0.00% |
| Total Other Income/Expenses | 6.47K | -6.47K | -53.28K |
| Income Before Tax | -9.21M | -2.00M | -17.70K |
| Income Before Tax Ratio | -1,259.40% | -22,352.11% | 0.00% |
| Income Tax Expense | 0.00 | -224.62K | -70.08K |
| Net Income | -9.21M | -2.00M | -17.70K |
| Net Income Ratio | -1,259.40% | -22,352.11% | 0.00% |
| EPS | -6.45 | -0.12 | 0.00 |
| EPS Diluted | -6.45 | -0.12 | 0.00 |
| Weighted Avg Shares Out | 1.43M | 17.32M | 17.32M |
| Weighted Avg Shares Out (Dil) | 1.43M | 17.32M | 17.32M |
Mangoceuticals Granted 180-Day Extension to Meet Nasdaq Minimum Bid Price Requirement and Conditional Approval of Compliance with Nasdaq's Minimum Stockholders' Equity Requirement
Dallas, Texas, May 02, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling a variety of men's health and wellness products in the area of erectile dysfunction (ED), hair...
Mangoceuticals Subsidiary, MangoRx Mexico, Executes Technical Agreement with Mexican Pharmaceutical Manufacturer for Initial Development and Production of its Mango Erectile Dysfunction (ED) Products
Signifies the first major step towards the application process for the certification of its Mango ED oral dissolvable products by Mexico's health governing agency, COFEPRIS
MangoRx Officially Launches ‘PRIME' by MangoRx, Powered by Kyzatrex®️ FDA Approved Oral Testosterone Replacement Therapy (TRT) Treatment
The Dallas Based, Direct-to-Consumer Telemedicine Company Brings the FDA-Approved Oral Testosterone Replacement Therapy Treatment to the Telehealth Market
MangoRx Launches Direct-To-Clinics Sales Division to Drive and Fuel Customer Acquisition and Revenue Growth
Newly developed clinic prescribing system will allow Doctors to prescribe MangoRx products from within practices and clinics
MANGORX TO OFFER THE BIG GAME'S LOSING TEAM A FREE ONE YEAR SUPPLY OF ITS ED PRODUCT, MANGO, TO HELP RAISE
MangoRx Wants to Keep Fumbles on the Field, Not in the Bedroom, Offering the Losing Team Free MangoRx ED Products for One Year
MangoRx Accepting Pre Orders for its “PRIME”, by MangoRx, Powered by Kyzatrex®️ FDA Approved Oral Testosterone Replacement Therapy (TRT) Product
The Dallas Based, Direct-to-Consumer Telemedicine Company to Offer 2 Months of Free ‘PRIME' by MangoRx, Powered by Kyzatrex®️ (a $498 value) for First 1,000 Subscribers
MangoRx's Brand and Products to be Featured by Barstool Sports in Week of Programming Around the Biggest Sports Event of the Year on February 11
"King of the Internet" Dave Portnoy's Uber-Popular Sports Media Company to Spotlight FDA-Approved Oral Testosterone Replacement ‘Prime' by MangoRx, Powered by Kyzatrex®
Mangoceuticals, Inc. Announces Pricing of $1,200,000 Public Offering
Dallas, Texas, Dec. 15, 2023 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (Nasdaq: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling a variety of men's health and wellness products via a secure telemedicine platform, including its uniquely...
Why Is Mangoceuticals (MGRX) Stock Down 33% Today?
Mangoceuticals (NASDAQ: MGRX ) stock is dropping on Friday after the men's wellness products company launched a stock offering this morning. That stock offering has the company selling 5 million shares of MGRX stock.
MANGOCEUTICALS TO INTRODUCE “PRIME”, POWERED BY KYZATREX®️ (CIII TESTOSTERONE UNDECANOATE CAPSULES), FOR AN FDA APPROVED ORAL TESTOSTERONE REPLACEMENT THERAPY (TRT) PRODUCT
The Dallas Based, Direct-to-Consumer Telemedicine Company Secures Marketing Agreement with Marius Pharmaceuticals Bringing KYZATREX to the Telehealth Market as ‘Prime' by MangoRx
Source: https://incomestatements.info
Category: Stock Reports